This correlates to a distinct CD8+ T cell-driven systemic GVHD peak at d14, which was followed by a CD4+ T cell-driven phase at later time points, as well as scleroderma-like chronic GVHD symptoms, as reported in [25]. The gene discussed is CD8A; the disease is scleroderma.